Journey Advisory Group LLC Purchases 101 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Journey Advisory Group LLC lifted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 12.9% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 884 shares of the medical equipment provider’s stock after buying an additional 101 shares during the period. Journey Advisory Group LLC’s holdings in Intuitive Surgical were worth $393,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in ISRG. Advisors Asset Management Inc. boosted its position in Intuitive Surgical by 18.1% during the 1st quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider’s stock valued at $2,945,000 after acquiring an additional 1,129 shares in the last quarter. Public Employees Retirement System of Ohio grew its stake in Intuitive Surgical by 5.4% in the fourth quarter. Public Employees Retirement System of Ohio now owns 191,283 shares of the medical equipment provider’s stock valued at $64,531,000 after purchasing an additional 9,869 shares during the last quarter. HCR Wealth Advisors raised its holdings in Intuitive Surgical by 26.3% in the fourth quarter. HCR Wealth Advisors now owns 1,042 shares of the medical equipment provider’s stock worth $352,000 after purchasing an additional 217 shares in the last quarter. Checchi Capital Advisers LLC lifted its position in shares of Intuitive Surgical by 2.5% during the fourth quarter. Checchi Capital Advisers LLC now owns 2,875 shares of the medical equipment provider’s stock valued at $970,000 after buying an additional 70 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Intuitive Surgical by 0.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 519,807 shares of the medical equipment provider’s stock valued at $175,364,000 after buying an additional 4,335 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on ISRG shares. Citigroup boosted their price objective on shares of Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Redburn Atlantic raised Intuitive Surgical from a “neutral” rating to a “buy” rating and upped their price target for the stock from $380.00 to $510.00 in a research report on Friday, August 2nd. Truist Financial raised their price objective on Intuitive Surgical from $450.00 to $515.00 and gave the stock a “buy” rating in a research report on Tuesday, July 16th. BTIG Research upped their target price on Intuitive Surgical from $469.00 to $494.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th. Finally, Robert W. Baird raised their price target on Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a report on Friday, July 19th. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $446.45.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, EVP Robert Desantis sold 239 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $416.60, for a total value of $99,567.40. Following the completion of the transaction, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at $2,293,799.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Intuitive Surgical news, EVP Robert Desantis sold 239 shares of Intuitive Surgical stock in a transaction on Monday, June 10th. The shares were sold at an average price of $416.60, for a total value of $99,567.40. Following the completion of the transaction, the executive vice president now owns 5,506 shares of the company’s stock, valued at $2,293,799.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Henry L. Charlton sold 40,243 shares of the stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the sale, the senior vice president now directly owns 3,001 shares in the company, valued at $1,461,006.84. The disclosure for this sale can be found here. Insiders have sold 51,656 shares of company stock worth $24,700,644 over the last quarter. 0.90% of the stock is currently owned by insiders.

Intuitive Surgical Price Performance

ISRG stock opened at $476.69 on Friday. The company has a market capitalization of $169.08 billion, a P/E ratio of 86.05, a price-to-earnings-growth ratio of 5.43 and a beta of 1.39. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $493.97. The firm’s fifty day simple moving average is $458.20 and its 200-day simple moving average is $417.34.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, beating the consensus estimate of $1.54 by $0.24. The company had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm’s revenue was up 14.5% on a year-over-year basis. During the same period in the prior year, the company earned $1.18 earnings per share. As a group, sell-side analysts forecast that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.